Regeneron 2025-26: DUPIXENT Hits $17.8B (+32% cc)
FY25 revenue $14.34B (+1%); Op income $3.58B (-10%); NI $4.50B (+2%); EPS $41.48 (+8%). DUPIXENT $17.8B FY25 (+32% cc) — but partner-share economics; LIBTAYO +13% to $1.45B; EYLEA HD growth despite category challenges. R&D step up FY26 $5.9-$6.1B. Op margin compressed on R&D + EYLEA franchise mix.
Key takeaways
- DUPIXENT continues compounding at scale. Q4 global net sales $4.9B; full year $17.8B (+32% constant currency). Now used by 1.4M+ patients globally across 8 indications. The Sanofi-partnered drug remains the structural growth engine, though Regeneron books R&D + commercial spend.
- EYLEA HD (high-dose) penetration vs EYLEA cannibalization. EYLEA HD growth despite category challenges, but the EYLEA franchise as a whole faces biosimilar pressure. The transition from original EYLEA to HD is the FY26 swing factor.
- LIBTAYO accelerating in non-oncology indications. Q4 $425M / FY $1.45B (+13% cc). Leading immunotherapy for advanced non-melanoma skin cancers + expanding indications.
- R&D budget stepping up to $5.9-$6.1B FY26 (vs ~$5.5B FY25). Pipeline includes mutant CALR MPN, axatilimab cGVHD additional indications, multiple oncology + autoimmune candidates.
- EPS +8% on flat revenue reflects buyback discipline ($-3.4B FY25) + tax efficiency. Operating income compressed -10% on R&D investment + EYLEA mix shift.
Business
Regeneron Pharmaceuticals is a fully-integrated biotech with three commercial franchises + a deep R&D engine:
- DUPIXENT (dupilumab) (~38% of revenue, growing fastest): Anti-IL-4Rα biologic. Indications: atopic dermatitis (eczema), asthma, CRSwNP (sinusitis with nasal polyps), prurigo nodularis, EoE (eosinophilic esophagitis), COPD (chronic obstructive pulmonary disease), bullous pemphigoid, urticaria. Partner: Sanofi (50/50 collaboration; Regeneron gets profit share).
- EYLEA + EYLEA HD (aflibercept) (~30% of revenue, transitioning): Anti-VEGF for retinal diseases (wet AMD, diabetic macular edema, retinal vein occlusion, diabetic retinopathy). EYLEA HD high-dose 8mg formulation extends dosing intervals; FY25-26 = transition year as HD penetration accelerates against biosimilar entry into original EYLEA.
- LIBTAYO (cemiplimab) (~10% of revenue): Anti-PD-1 immunotherapy for advanced cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma, non-small cell lung cancer (NSCLC), cervical cancer.
- Other commercial + collaborations: Praluent + Kevzara + Inmazeb + Veopoz + collaboration revenue from Sanofi + Bayer.
The R&D engine: ~10 unique mAbs in clinical development including Linvoseltamab (BCMA bispecific for multiple myeloma), Odronextamab (CD20×CD3 bispecific for lymphoma), Itepekimab (anti-IL-33 for COPD), Garetosmab (activin A for FOP), Pozelimab + Cemdisiran combo, Alnylam-partnered RNAi candidates.
FY25 financial performance
| Metric (FY) | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue ($B) | 13.12 | 14.20 | 14.34 |
| Gross profit ($B) | 10.87 | 12.23 | 12.24 |
| Op income ($B) | 4.35 | 3.99 | 3.58 |
| Op margin | 33.2% | 28.1% | 24.9% |
| EBITDA ($B) | 4.69 | 5.32 | 5.82 |
| Net income ($B) | 3.95 | 4.41 | 4.50 |
| Diluted EPS ($) | 34.77 | 38.34 | 41.48 |
| FCF ($B) | 3.67 | 3.66 | 4.08 |
| Capex ($M) | -926 | -756 | -898 |
| Total debt ($B) | 2.70 | 2.70 | 2.71 |
| Dividends ($M) | 0 | 0 | -370 |
| Buyback ($B) | -2.94 | -3.63 | -3.44 |
The earnings print:
- Revenue +1% on flat-to-growing core portfolio with DUPIXENT carrying offset by EYLEA mix.
- Op margin compressed -320bp to 24.9% on R&D step-up + EYLEA mix.
- EPS +8% on buyback shrink ($3.4B/yr).
- Initiated dividend program FY25 ($-370M).
Capital allocation
- Capex: $-898M FY25 (6.3% of revenue). Manufacturing capacity + R&D facility. Capital-intensive growth period.
- Dividends: Initiated FY25 at $-370M (~$3.10/share annual). New dividend signal.
- Buybacks: $-3.44B FY25, consistent with $3-3.6B/year cadence.
- R&D: ~$5.5B FY25 → $5.9-$6.1B FY26 guide.
- Net cash position; total debt $2.71B held steady.
FY26 outlook (per Q4 2025 call, 2026-01-30)
| FY26 guide | Range |
|---|---|
| R&D spend | $5.9B-$6.1B |
| SG&A | $2.5B-$2.65B |
| Gross margin | 83%-84% |
| Capex | $1.1B-$1.3B |
| Effective tax rate | 13%-15% |
Implicit revenue + EPS guidance not provided, but bridge: DUPIXENT continued ~+25-30% growth on indication expansion + market growth; LIBTAYO mid-teens; EYLEA HD growth offsetting EYLEA decline; LIBTAYO continued 15%+. Net consolidated revenue +mid-single-digit FY26 likely.
R&D step-up + capex normalization compress operating margin further; this is the investment phase before next-wave commercial launches.
Key risks
- EYLEA biosimilar erosion: Original EYLEA 2mg facing biosimilar competition. EYLEA HD (8mg) penetration must offset the decline; if HD adoption slows, the franchise compresses faster than expected.
- DUPIXENT competition: Other Th2-pathway biologics (Tezspire, Adbry, Nemolizumab) competing in eczema + asthma. Pricing + indication competition flow through.
- Regulatory / FDA: 100+ Phase 3 trials; readout success rate matters. 20+ readouts expected in 2026 with potential >$10B peak revenue from approvals (per AZN-cited data).
- Sanofi partnership: DUPIXENT economics depend on the 50/50 split; partnership renegotiation or strategic shift would affect economics.
- R&D pipeline failures: Linvoseltamab + Odronextamab + Itepekimab depend on Phase 3 success.
- US Inflation Reduction Act: Medicare drug-price-negotiation list could include EYLEA + DUPIXENT in future cycles.
Bottom line
REGN FY25 is the operating margin investment year — revenue +1%, op margin -320bp on R&D + EYLEA mix, but EPS +8% on buyback discipline. DUPIXENT at $17.8B (+32% cc) remains the structural growth engine; EYLEA → EYLEA HD transition is the FY26 swing factor; LIBTAYO + pipeline candidates the future earnings drivers. R&D step-up to $5.9-$6.1B FY26 + dividend initiation + buyback continuation framing the next phase. Risks are EYLEA biosimilar pace, DUPIXENT competition, and R&D pipeline execution. At net cash + 84% gross margin + 1.4M+ DUPIXENT patients, this is structurally one of the highest-quality biotech compounders.
Citations
- Regeneron Pharmaceuticals Inc. FY25 Form 10-K (filed February 2026, SEC EDGAR).
- Regeneron Q4 2025 earnings call, 2026-01-30 — DUPIXENT $17.8B FY25 (+32% cc), 1.4M+ patients globally; LIBTAYO $1.45B (+13% cc); FY26 guide (R&D $5.9-$6.1B, SG&A $2.5-$2.65B, GM 83-84%, capex $1.1-$1.3B, tax rate 13-15%).
- Internal financial_statements view (consolidated annual + cash flow + capital return).